https://hotcopper.com.au/documentembed?id=uOMxKKzFkiWRTLKhOROKAxjvTDYD4Aq%2ByxSZovhtke92GA%3D%3D
ASX/Media Release
20 June 2019
BTX 1801 kills superbugs without resistance: world-first study
BTX 1801 is a novel topical formulation of cannabidiol which utilises Botanix’s proprietary skin delivery technology, Permetrex TM, to target bacterial infections in the skin. Previous studies conducted by Botanix in collaboration with Dr Blaskovich had demonstrated that cannabidiol has the potential to be a broad-spectrum Gram-Positive antibiotic. These new studies confirm these initial findings and now show the potential for cannabidiol formulated as BTX 1801 to treat serious skin infections. For the first time globally, results from these new studies have shown that:
1. BTX 1801 is a broad-spectrum Gram-Positive antibiotic which is effective against a range of problematic human and animal bacteria: Cannabidiol was remarkably effective at killing a range of Gram-Positive bacteria, with potencies similar to powerful antibiotics such as vancomycin and daptomycin;
2. BTX 1801 is effective against clinical isolates of staphylococcus aureus (“staph”) and methicillin resistance staphylococcus aureus (“MRSA”): A diverse panel of 132 clinical isolates of staph and MRSA were tested and cannabidiol is effective at low concentrations against all of these clinical isolates;
3. Bacteria do not form resistance to cannabidiol: In industry standard repeat challenge tests,
MRSA bacteria did not develop resistance after 21 days of continuous treatment;
4. Cannabidiol kills bacteria very quickly: The killing activity is bactericidal not bacteriostatic –killing bacteria in less than 3 hours;
5. Cannabidiol disrupts biofilms that bacteria use to protect themselves: Disrupts bacterial biofilms, the protective film bacteria surround themselves with to protect against antibiotics;
6. BTX 1801 is effective in animal models: BTX 1801 has been shown in independent testing to be effective in a proof of concept animal wound model of skin infection (not just in the laboratory); and
7. Broad anti-inflammatory properties relevant to infections: BTX 1801 acts via a novel and previously undisclosed mechanism of action (as outlined in the recently announced BTX 1308 mechanism of action study that identified a novel anti-inflammatory pathway for cannabidiolin skin disease).